Evidence map›Paper›PMID 35402258›Full record

ArticleFrontiers in oncology2022

Enhanced Cancer Therapy Using an Engineered Designer Cytokine Alone and in Combination With an Immune Checkpoint Inhibitor.

Anjan K Pradhan, Praveen Bhoopathi, Santanu Maji, Amit Kumar, Chunqing Guo, Padmanabhan Mannangatti, Jiong Li, Xiang-Yang Wang, Devanand Sarkar, Luni Emdad and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Natural and Engineered Cytokines as Cancer Therapeutics.Annual review of cancer biology · 2026
    Article
  2. Novel fusion superkine,Journal for immunotherapy of cancer · 2025
    Article
  3. Article
  4. Article
  5. Review
  6. Review
  7. Interleukin-24: A Multidimensional Therapeutic for Treatment of Human Diseases.Wiley interdisciplinary reviews. Nanomedicine and nanobiotechnology
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Anjan K PradhanDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Praveen BhoopathiDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Santanu MajiDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Amit KumarDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Chunqing GuoDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Padmanabhan MannangattiDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Jiong LiVirginia Commonwealth University (VCU) Institute of Molecular Medicine, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Xiang-Yang WangDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Devanand SarkarDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Luni EmdadDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Swadesh K DasDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Paul B FisherDepartment of Human and Molecular Genetics, Virginia Commonwealth University, School of Medicine, Richmond, VA, United States.
Virginia Commonwealth University · US

Funding

Interplay between tumor and microenvironment in bone metastasisR01CA259599 · NCI · VIRGINIA COMMONWEALTH UNIVERSITY · PI FISHER, PAUL B, WANG, XIANG-YANG SHAWN · 2021 to 2025
$2.3M
NCI NIH HHS R01 CA259599
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

insulin signal peptide; PD-L1M7S (IL-24S)mda-7 (IL-24)melanomasecretory motif

Identifiers

PMID35402258
PMCPMC8988683
OpenAlexW4221013727

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.